Article
TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target.
Nature communications - 21 Jul 2020
Yu Jiao-Jiao, Zhou Dan-Dan, Yang Xiao-Xiao, Cui Bing, Tan Feng-Wei, Wang Junjian, Li Ke, Shang Shuang, Zhang Cheng, Lv Xiao-Xi, Zhang Xiao-Wei, Liu Shan-Shan, Yu Jin-Mei, Wang Feng, Huang Bo, Hua Fang, Hu Zhuo-Wei
Abstract excerpt
High expression or aberrant activation of epidermal growth factor receptor (EGFR) is related to tumor progression and therapy resistance across cancer types, including non-small cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitors (TKIs) are first-line therapy for NSCLC. However, patients eventually deteriorate after inevitable acquisition of EGFR TKI-resistant mutations, highlighting the need for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.